Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinical Usefulness of Serum CYFRA 21–1 in Patients with Colorectal Cancer

Clinical Usefulness of Serum CYFRA 21–1 in Patients with Colorectal Cancer Purpose Among diverse tumor markers, pretreatment evalu- useful and dependable tumor marker for pretreatment and ation and follow-up detection of recurrence in colorectal can- recurrent colorectal cancer. Further prospective studies on its cer are generally evaluated by serum carcinoembryonic anti- usefulness with respect to the prognosis and utility of com- gen (CEA) levels. However, there have been some reports bined tumor markers are needed. about the low accuracy and high false-positive results of CEA . . in colorectal cancer. We investigated the clinical utilities of Keywords Colorectal cancer CYFRA 21–1 CYFRA 21–1 by comparing CEA and cancer antigen 19–9 CEA and CA 19–9 (CA 19–9) in pretreatment and recurrent colorectal cancer. Methods Using a solid-phase immunoradiometric assay, serum levels of CYFRA 21–1, CEA and CA 19–9wereanalyzedin Introduction 132 patients with primary colorectal cancer, 124 healthy con- trols, 104 patients with benign colorectal disease and 19 pa- Colorectal carcinoma (CRC) is one of the significant causes of tients with recurrent colorectal cancer. We determined three gradually global increased cancer death rate and morbidity, different cutoff values to evaluate the sensitivity of diagnostic with rising incidence in Korea. The American Cancer Society performance in pretreatment and recurrent colorectal cancer. reported 101,340 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nuclear Medicine and Molecular Imaging Springer Journals

Clinical Usefulness of Serum CYFRA 21–1 in Patients with Colorectal Cancer

Lee, Jai
Nuclear Medicine and Molecular Imaging , Volume 47 (3) – Aug 6, 2013
Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/clinical-usefulness-of-serum-cyfra-21-1-in-patients-with-colorectal-m9Sn8cb4cY

References (37)

Publisher
Springer Journals
Copyright
Copyright © 2013 by Korean Society of Nuclear Medicine
Subject
Medicine & Public Health; Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology
ISSN
1869-3474
eISSN
1869-3482
DOI
10.1007/s13139-013-0218-4
pmid
24900105
Publisher site
See Article on Publisher Site

Abstract

Purpose Among diverse tumor markers, pretreatment evalu- useful and dependable tumor marker for pretreatment and ation and follow-up detection of recurrence in colorectal can- recurrent colorectal cancer. Further prospective studies on its cer are generally evaluated by serum carcinoembryonic anti- usefulness with respect to the prognosis and utility of com- gen (CEA) levels. However, there have been some reports bined tumor markers are needed. about the low accuracy and high false-positive results of CEA . . in colorectal cancer. We investigated the clinical utilities of Keywords Colorectal cancer CYFRA 21–1 CYFRA 21–1 by comparing CEA and cancer antigen 19–9 CEA and CA 19–9 (CA 19–9) in pretreatment and recurrent colorectal cancer. Methods Using a solid-phase immunoradiometric assay, serum levels of CYFRA 21–1, CEA and CA 19–9wereanalyzedin Introduction 132 patients with primary colorectal cancer, 124 healthy con- trols, 104 patients with benign colorectal disease and 19 pa- Colorectal carcinoma (CRC) is one of the significant causes of tients with recurrent colorectal cancer. We determined three gradually global increased cancer death rate and morbidity, different cutoff values to evaluate the sensitivity of diagnostic with rising incidence in Korea. The American Cancer Society performance in pretreatment and recurrent colorectal cancer. reported 101,340

Journal

Nuclear Medicine and Molecular Imaging – Springer Journals

Published: Aug 6, 2013

There are no references for this article.